Previous 10 | Next 10 |
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021. The Nasdaq Biotechnology Index (NBI) is designed to meas...
EyePoint Pharmaceuticals (NASDAQ:EYPT) and ImprimisRx, a subsidiary of Harrow Health (NASDAQ:HROW), have expanded an alliance under which Imprimis is now responsible for marketing of Dexycu (dexamethasone intraocular suspension) for post-operative inflammation. ImprimisRx will assume sales an...
WATERTOWN, Mass. and NASHVILLE, Tenn. and CARLSBAD, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, an...
Even though the company failed to fit the analysts' expectations for EPS, the company's financial indicators are growing. The company's gross margin is growing, operating expenses are decreasing, and revenue growth rate maintains a positive trend. We expect the company continues to in...
The following slide deck was published by Harrow Health, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Harrow Health, Inc. 2021 Q3 - Results - Earnings Call Presentation
Harrow Health, Inc. (HROW) Q3 2021 Earnings Conference Call November 9, 2021 4:45 PM ET Company Participants Jamie Webb – Director of Communications and Investor Relations Mark L. Baum – Chief Executive Officer Andrew Boll – Chief Financial Officer Conference Call Partici...
Harrow Health (NASDAQ:HROW): Q3 GAAP EPS of -$0.31 misses by $0.28. Revenue of $18.7M (+29.9% Y/Y) beats by $1.25M. Press Release For further details see: Harrow Health EPS misses by $0.28, beats on revenue
Revenues Reach Record Levels for Fifth Consecutive Quarter Highlights for Third Quarter 2021: Record revenues of $18.7 million, a 30% increase compared with $14.4 million for the prior-year period; Gross margin of 74% consistent with prior-year period; Acquired...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the third quarter and nine months ended September 30, 2021, on Tuesday, November 9, 2021, after the market close. The Company will also pos...
Melt Expects to Dose First Patient in MELT-300 Phase 2 Study During September 2021 Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for se...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...